CDSCO approves India's first CAR-T cell therapy against certain blood cancers
Laurus Labs on Friday said it has received approval from Indian drug regulator the Central Drugs Standard Control Organization (CDSCO) for its CAR-T cell therapy NexCAR19 (actalycabtagene autoleucel), for the treatment of certain types of blood cancers.
NexCAR19 will be the first humanized CD19-targeted Chimeric Antigen Receptor T cell (CAR-T) therapy indigenously developed in India to be approved.
Enhance Your Healthcare Expertise with High-Impact Courses
Offering CollegeCourseWebsiteIIM KozhikodeIIMK Healthcare Management & Analytics ProgrammeVisitNexCAR19 will be used for treating relapsed/refractory (r/r) B-cell lymphomas and leukemia in India.
ImmunoACT didn't reveal the pricing of the drug, but said it intends to make the NexCAR19 available to its partner hospitals as soon as possible.
ImmunoACT's founder and CEO Rahul Purwar has in the past announced that its CAR-T cell therapy would be priced anywhere between Rs 30 lakh and Rs 40 lakh per patient, a lot cheaper compared to existing treatments. Each patient's CAR-T cell therapy costs 3-4 crore (INR).
The multi-center phase I/II pivotal clinical trial, led by Dr Hasmukh Jain, was conducted with 60 patients of r/r B-cell lymphomas and leukemia.
The clinical data indicates 70% overall response rate (ORR). The safety profile in terms of cytokine release syndrome (CRS) and low-toxicity indicating a significant improvement over the other
commercially approved CD19-directed CAR-T cell therapies.
NexCAR19 is a collaborative effort across a decade, between the IIT-Bombay, and Tata Memorial Centre (TMC). Atharva Karulkar, Alka Dwivedi and the team led by Rahul Purwar, associate professor at IIT Bombay designed and developed the NexCAR19, which subsequently underwent
